

# Expanding the Scope of Orthogonal Translation with Pyrrolysyl-tRNA Synthetases Dedicated to Aromatic Amino Acids

## Supplementary Information

Hsueh-Wei Tseng <sup>1</sup>, Tobias Baumann <sup>1</sup>, Huan Sun <sup>1</sup>, Yane-Shih Wang <sup>2,3</sup>, Zoya Ignatova <sup>4</sup>, and Nediljko Budisa <sup>1,5,\*</sup>

<sup>1</sup> Institut für Chemie, Technische Universität Berlin, Müller-Breslau-Straße 10, 10623 Berlin, Germany; justin3926@hotmail.com (H.W.T.); tobias.baumann@tu-berlin.de (T.B.); huansunluck@gmail.com (H.S.); nediljko.budisa@tu-berlin.de (N.B.).

<sup>2</sup> Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan; yaneshihwang@gate.sinica.edu.tw (Y.S.W.)

<sup>3</sup> Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan

<sup>4</sup> Institute of Biochemistry and Molecular Biology, University of Hamburg, 20146 Hamburg, Germany; zoya.ignatova@uni-hamburg.de (Z.I.)

<sup>5</sup> Department of Chemistry, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; nediljko.budisa@umanitoba.ca (N.B.)

\* Correspondence: nediljko.budisa@tu-berlin.de or nediljko.budisa@umanitoba.ca; Tel.: +49-30-314-28821 or +1-204-474-9178 (N.B.)

## Note S1. DNA sequences

Sequence of the *MmPylRS* gene used in this study. Mutation sites for expanding the aaRS substrate range (L305, Y306, L309, N346, C348, V401, and W417) highlighted in yellow; mutation sites for improving the aaRS efficiency (T13, V31, I36, T56, R61, H62, H63, A100, and S193) highlighted in green.

```
atggataaaaaaccactaaacactctgatctcgaacgggctctggatgtccaggaccggaacaattcataaaaaataaacaccacgaaagctctcgaagcaaaa  
ctatattgaaatggcatgaggagaccactgtgtgtaaaactccaggagcagcaggctgcaagagcgcctcaggcaccacaatacagggaagacctgcaaac  
gctgcaagggttcggatgaggatctcaataagttctcacaaggcaaacgaagaccagcaagcgtaaaagtcaaggtcgttctgcccctaccagaacgaaaa  
aggcaatgccaaaatccgttgcgagagccccgaaacctcttgagaatacagaagcggcacaggctcaacctctggatctaaatttcacctgcgataccggttcc  
acccaagagtcagtttctgcccggcatctgttcaacatcaatcaagcattttacaggagcaactgcacccgactggtaaaagggaatacgaacccattaca  
tccatgtctgcccgttcaggcaagtcccccgacttacgaagggcagactgacaggctgaagctctgttaaacccaaaagatgagatttccctgaattccgg  
caagccttcaggagccttgagtcgaattgctctcgcagaaaaaagacctgcagcagatctacgcggaagaaaggagaattatctgggaaactgcagc  
gtgaaattaccaggttcttctggacaggggttctggaataaaatccccgatctgatccctctgagtatatcgaagagatgggcattgataatgataccgaa  
ctttcaaacagatctcagggttgacaagaactctgctgagaccatgcttctcacaaccttacaactacctgcgcaagcctgacagggccctgctgatcca  
ataaaaaattttgaaataggccatgctacagaaaagagtcgacggcaagaacacctgaaagagttaccatgctgaacttctgccaagatgggatcgggatgc  
acacgggaaaaatctgaaagcataattacgacttctgaaccacctgggaattgattcaagatcgtaggcgattctgcatggtctatggggatacccttgatg  
aatgcacggagacctggaacttctctgagtagtcggaccataaccgctgaccgggaatggggattgataaacctgggataggggcaggttccggctcga  
acgcttctaaaagttaaacacgacttcaaaaaatcaagagagctgcaaggtccgagcttactataacgggatttctaccaacctgtaa
```

Sequence of the codon-optimized *MmPylRS* gene used in this study.

```
atggataaaaaaccactaaacactctgatctcgtactgctgtgtggatgagtcgtaccggaaccattcataaaaatcaaacaccacgaggttagccgttcgaaaa  
ctatattgagatggcgtgtggcgcacatctggtgtgaaatagccgctctctctctacagcagctgcactgcctcaccacaatatacgtaaaacctgtaaacgtt  
gccgtgttccgatgagatctgaacaaattctgacaaaagccaatgaggaccaaaaagcgtgaaagtgaagtcgttagcgcctcctaccctactaaaaaag  
caatgccaaaatccgttctcgtgcccccaaacactggaanaacactgaagcagcacagcagccgctggaagcaaatctctccggcattcctgttctacc  
caggagtcctgttctgccaaggtgtgagcaccagcattagcagatttagcaccggtgccaccgctagcgcctggtaaaaggcaataccaatccgattacaa  
gcatgtctgcccggttcaagcatcagctccagcactgacaaaatcccaaacgatcgtctggaggttctgctgaatccgaaagacgaaatcagcctgaattccgg  
caaaccttctcgtgaactggagagcgaactgctgtcagctgtaaaaaagacctgcaaaaatctatgccgaagacgtgagaactatctgggaaactggaac  
gtgaaatcaccgcttttctggtgatcgtggcttctggagatcaaatccccgattctgattcctctggagtatatcgagcgtatgggcatcgacaatgataccgaa  
tgagcaaaaatatttccgtgtgataaaaaacttctgctgcgccctatgctggcacaatctgtataactatctgcgcaaacctggaccgtgcctgctgatctat  
caaaaatctcgagatcgcccgtgtatcgtaaagagtcgacggtaaaagaacatctggaggagttaccatgctgaacttttccaatgggttcagggtgtactc  
gtgagaacctggaagcatcaccgatttctgaaccacctggcattgacttcaaaattgtggcgacagctgtatggtgtatggcgaccctggatgcat  
gcacggcagactggaactgtctagtccgttgtggaccaatccgctggaccgtgagtggggtatcgacaaacctggatcgagcaggttccgctcgtgaaac  
gctgctgaaagtgaacacgacttcaaaaacatcaaacgtgcccccgttctgaatcgtattataacgggatttctaccaacctgtaa
```

Sequence of the stop codon suppression reporter sfGFP-R2TAG with the in-frame amber stop codon (sfGFP position 2) highlighted in red.

```
atgtagaaaggcgaagagctgtcactggtgctcctattctggtgaaactggatggtgatgtcaacggtcataagtttccgtcgtggcgagggtgaaggt  
gacgcaactaatggtaactgacgtgaagttcatctgtactactgtaaaactccggtaacctggccgactctggttaacgacgctgacttatggtgtcagtgctt  
gctcgttatccggaccatatgaagcagcatgacttctcaagtccgccatgccggaaggctatgtgcaggaacgcacgatttctttaaaggatgacggcacgtaca  
aaacgcgtgcggaagtgaatttgaagcgataccctgtaaacccgattgagctgaaaggcattgactttaaagaagacggcaatatcctggccataagctg  
gaatacaattttaaagccacaatgtttacatcaccgccgataaacaataaaatggcattaaagcgaattttaaattcgcacacactggaggatggcagcgtgc  
agctggctgatacactaccgcaaaaactccaatcgggtatggtcctgttctgctccagacaatcactatctgagcagcgaagcgttctgctaaagatccgaac  
gagaacgcgatcatatggttctgctggagttcgtaacccagcgggcatcacgatggtatgatgaactgtacaaaggcagccatcatcatcatcatcaaa
```

## Note S2. Primer list

Name	Sequence (5' ->3')
PylRS_pBU_F	AGAGGCATATGGATAAAAAACCACTAAACACTCTG
PylRS_pBU_R	AGAGGGGTACCAAAGCAGAAAAACGCCGCTGAAC
<i>MmPylRS</i> - N346G/C348Q_F	CACCTCGAAGAGTTTACCATGCTGGGCTTCCAGCAGATGG GATCGG
<i>MmPylRS</i> - N346G/C348Q_R	CCGTGTGCATCCCATCCCATCTGCTGGAAGCCCAGCATG GTAAACTC
<i>MmPylRS</i> - N346A/C348Q_F	CACCTCGAAGAGTTTACCATGCTGGCGTTCAGCAGATGG GATCGG
<i>MmPylRS</i> - N346A/C348Q_R	CCGTGTGCATCCCATCCCATCTGCTGGAACGCCAGCATG GTAAACTC
<i>MmPylRS</i> - N346S/C348Q_F	CACCTCGAAGAGTTTACCATGCTGAGCTTCCAGCAGATGG GATCGG
<i>MmPylRS</i> - N346S/C348Q_R	CCGTGTGCATCCCATCCCATCTGCTGGAAGCTCAGCATG GTAAACTC
<i>MmPylRS</i> - N346S/C348M_F	CACCTCGAAGAGTTTACCATGCTGAGCTTCATGCAGATGG GATCGG
<i>MmPylRS</i> - N346S/C348M_R	CCGTGTGCATCCCATCCCATCTGCATGAAGCTCAGCATG GTAAACTC
<i>MmPylRS</i> - N346G/C348M_F	CACCTCGAAGAGTTTACCATGCTGGGCTTCATGCAGATGG GATCGG
<i>MmPylRS</i> - N346G/C348M_R	CCGTGTGCATCCCATCCCATCTGCATGAAGCCCAGCATG GTAAACTC
<i>MmPylRS</i> - N346A/C348M_F	CACCTCGAAGAGTTTACCATGCTGGCGTTCATGCAGATGG GATCGG
<i>MmPylRS</i> - N346A/C348M_R	CCGTGTGCATCCCATCCCATCTGCATGAACGCCAGCATG GTAAACTC
<i>MmPylRS</i> - L305M/Y306L/L309A_F	GACCCATGCTTGCTCCAAACATGCTGAACTACGCGCGCAA GCTTG
<i>MmPylRS</i> - L305M/Y306L/L309A_R	GGGCCCTGTCAAGCTTGCGCGCGTAGTTCAGCATGTTTGG AGCAAGC
<i>MmPylRS</i> - L305M/Y306L/L309S_F	GACCCATGCTTGCTCCAAACATGCTGAACTACAGCCGCAA GCTTG
<i>MmPylRS</i> - L305M/Y306L/L309S_R	GGGCCCTGTCAAGCTTGCGGCTGTAGTTCAGCATGTTTGG AGCAAGC
<i>MmPylRS</i> -W417NNK_F	GAATGGGGTATTGATAAACCCNNKATAGGGGCAGGTTTC G
<i>MmPylRS</i> -W417NNK_R	TTCGAGCCCGAAACCTGCCCTATMNNGGGTTTATCAATA C
<i>MmPylRS</i> -V401NNK_F	GACCTGGAACCTTCTCTGCANNKGTCCGACCCATAACCG
<i>MmPylRS</i> -V401NNK_R	CCGTCAAGCGGTATGGGTCCGACMNNNTGCAGAGGAAAG CAGGCAAGTGCCCCCGCACTTACGAAGNNKCAGACTGAC
<i>MmPylRS</i> -S193NNK_F	AG
<i>MmPylRS</i> -S193NNK_R	GACTTCAAGCCTGTCAGTCTGMNNCTTCGTAAGTGCG
<i>MmPylRS</i> -T13I_NdeI_F	AGAGGCATATGGATAAAAAACCACTAAACACTCTGATAT CTGCAATCGGG
<i>MmPylRS</i> _V31I_F	CATAAAATAAAACACCACGAAATTTCTCGAAGCAAATC
<i>MmPylRS</i> _V31I_R	CAATATAGATTTTGTCTCGAGAAATTCGTGGTGTTC
<i>MmPylRS</i> -I36V_F	CACCACGAAGTCTCTCGAAGCAAAGTCTATATTG


<i>MmPyl</i> IRS-I36V_R	CATGCCATTTCAATATAGACTTTGCTTCGAGAGAC
<i>MmPyl</i> IRS-T56P_F	CTTGTTGTAAACAACCTCCAGGAGCAGCAGGCCCGCAAG
<i>MmPyl</i> IRS-T56P_R	GAGCGCTCTTGCGGGCCTGCTGCTCCTGGAGTTGTTTAC
<i>MmPyl</i> IRS-R61K_F	GCAGGACTGCAAGAGCGCTCAAACACCACAAATACAGGA AG
<i>MmPyl</i> IRS-R61K_R	TTTGCAGGTCTTCCTGTATTTGTGGTGTGTTGAGCGCTCTTG
<i>MmPyl</i> IRS-H62Y_F	GCAGGACTGCAAGAGCGCTCAGGTATCACAAATACAGGA AG
<i>MmPyl</i> IRS-H62Y_R	TTTGCAGGTCTTCCTGTATTTGTGATACCTGAGCGCTCTTG
<i>MmPyl</i> IRS-H63Y_F	GCAGGACTGCAAGAGCGCTCAGGCACTATAAATACAGGA AG
<i>MmPyl</i> IRS-H63Y_R	TTTGCAGGTCTTCCTGTATTTATAGTGCCTGAGCGCTCTTG
<i>MmPyl</i> IRS-R61K/H63Y_F	GCAGGACTGCAAGAGCGCTCAAACACTATAAATACAGGA AG
<i>MmPyl</i> IRS-R61K/H63Y_R	TTTGCAGGTCTTCCTGTATTTATAGTGTGTTGAGCGCTCTTG
<i>MmPyl</i> IRS_A100E_F	GCGTAAAAGTCAAGGTTCGTTTCTGAGCCTACCAGAACG
<i>MmPyl</i> IRS-A100E_R	GGCATTGCCTTTTTTCGTTCTGGTAGGCTCAGAAACGACC
<i>MmPyl</i> IRS-S193R_F	CAGGCAAGTGCCCCCGCACTTACGAAGCGTCAGACTGAC AG
<i>MmPyl</i> IRS-S193R_R	GACTTCAAGCCTGTCAGTCTGACGCTTCGTAAGTGCG
pBU16_co <i>MmPyl</i> IRS_Nd eI_F	AGAGGCATATGGATAAAAAACCACTAAACACTCTGATCT CTGCTACTG
pBU16_co <i>MmPyl</i> IRS_PstI _R	GAAACTGCAGTTTCCATGGTTACAGGTTGGTAGAAATCCC GTATAATAC
co <i>MmPyl</i> IRS- N346S/C348M_F	CTGGAGGAGTTTACCATGCTGAGCTTTATGCAAATGG
co <i>MmPyl</i> IRS- N346S/C348M_R	CAACCTGAACCCATTTGCATAAAGCTCAGCATGGTAAACT CC
co <i>MmPyl</i> IRS-V401G_F	GCGACCTGGAAGTGTCTAGTGCCGGCGTTGGACCAATTC
co <i>MmPyl</i> IRS-V401G_R	GTCCAGCGGAATTGGTCCAACGCCGGCACTAGACAGTTCC AGG
co <i>MmPyl</i> IRS- R61K/H63Y_F	GCTCTTCTCGTACAGCACGTGCACTGAAACACTATAAATA TC
co <i>MmPyl</i> IRS- R61K/H63Y_R	GTTTACAGGTTTTACGATATTTATAGTGTTCAGTGCACGT G
co <i>MmPyl</i> IRS-S193R_F	CAAGCATCAGCTCCAGCACTGACAAAACGTCAAACCGAT CGTC
co <i>MmPyl</i> IRS-S193R_R	GAACCTCCAGACGATCGGTTTTGACGTTTTGTCAGTGCTGG

---

## Supplementary Figure S1

The initial aaRS screening results indicated that the constructed *MmPylRS* variants were capable of activating Trp analogs. The *E. coli* strain BL21(DE3) was cultured in M9 minimal medium (with Amp and Kan) and distributed to 200  $\mu$ L in 96-wells plates containing different ncAAs (1 mM) in each well (see Table S2 and S3). The assay plates were incubated at 37  $^{\circ}$ C with shaking for 18 h. Fluorescence intensities and OD<sub>600</sub> were measured, the former via bottom reading (excitation wavelength of 481 nm, emission wavelength of 511 nm).


A.



Substrate range of *MmPylRS*-N346A/C348M/V401G.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS*-AMG as measured via the reporter fluorescence intensity.


B.



Substrate range of *MmPylRS*-N346G/C348M/V401G.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS*-GMG as measured via the reporter fluorescence intensity.


C.



Substrate range of *MmPylRS-N346A/C348Q/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-AQG* as measured via the reporter fluorescence intensity.


D.



Substrate range of *MmPylRS-N346G/C348Q/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-GQG* as measured via the reporter fluorescence intensity.


E.



Substrate range of *MmPylRS-N346S/C348Q/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-SQG* as measured via the reporter fluorescence intensity.


F.



Substrate range of *MmPylRS-L305M/Y306L/L309S/N346S/C348M*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-MLS\_SM* as measured via the reporter fluorescence intensity.


G.



Substrate range of *MmPylRS-R61K/H63Y/S193R/N346A/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_AMG* as measured via the reporter fluorescence intensity.

H.




Substrate range of *MmPylRS-R61K/H63Y/S193R/N346G/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_GMG* as measured via the reporter fluorescence intensity.




I.



Substrate range of *MmPylRS-R61K/H63Y/S193R/N346S/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_SMG* as measured via the reporter fluorescence intensity.


J.



Substrate range of *MmPylRS-R61K/H63Y/S193R/N346A/C348Q/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_AQG* as measured via the reporter fluorescence intensity.


K.



Substrate range of *MmPylRS-R61K/H63Y/S193R/N346G/C348Q/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_GQG* as measured via the reporter fluorescence intensity.


L.



Substrate range of *MmPylRS-T13I/I36V/N346S/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-IV\_SMG* as measured via the reporter fluorescence intensity.


M.



Substrate range of *MmPylRS-V31I/T56P/H62Y/A100E/N346S/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-IPYE\_SMG* as measured via the reporter fluorescence intensity.


N.



Substrate range of *MmPylRS-V31I/T56P/H62Y/A100E/S193R/N346S/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-IPYER\_SMG* as measured via the reporter fluorescence intensity.

O.




Substrate range of codon optimized *MmPylRS-N346S/C348M/V401G*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-coSMG* as measured via the reporter fluorescence intensity.

### Supplementary Figure S2

Reporter-based aaRS screening results indicating that mutations of PylRS residue W417 can lead to activation of Tyr analogs. The *E. coli* strain BL21(DE3) was cultured in M9 minimal medium (with Amp and Kan) and distributed to 200  $\mu$ L in 96-wells plates containing different ncAAs 1 mM in each well (see Table S2 and S3). The assay plates were incubated with shaking for 18 h at 37  $^{\circ}$ C. Fluorescence intensities and OD<sub>600</sub> were measured, the former via bottom reading (excitation wavelength of 481 nm, emission wavelength of 511 nm).


A.



Substrate range of *MmPylRS-N346A/C348M/W417L*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-AML* as measured via the reporter fluorescence intensity.


B.



Substrate range of *MmPylRS-N346S/C348M/W417V*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-SM\_W417V* as measured via the reporter fluorescence intensity.


C.



Substrate range of *MmPylRS-N346S/C348M/W417L*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-SML* as measured via the reporter fluorescence intensity.


D.



Substrate range of *MmPylRS-N346G/C348M/W417L*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-GML* as measured via the reporter fluorescence intensity.


E.



Substrate range of *MmPylRS-N346G/C348M/W417T*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-GMT* as measured via the reporter fluorescence intensity.


F.



Substrate range of *MmPylRS-N346G/C348M/W417V*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-GMV* as measured via the reporter fluorescence intensity.


G.



Substrate range of *MmPylRS-R61K/H63Y/S193R/N346S/C348M/W417I*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-KYR\_SM\_W417I* as measured via the reporter fluorescence intensity.

H.




Substrate range of codon optimized *MmPylRS-N346G/C348M/W417L*.

The library of amino acids was tested for incorporation into sfGFP-R2TAG by *MmPylRS-coGML* as measured via the reporter fluorescence intensity.

### Supplementary Figure S3


Comparison of Bta incorporation efficiency mediated by screened *MmPylRS* variants. Fluorescence was generated through suppression of the amber stop codon located in the reporter gene (sfGFP-R2TAG) by different *MmPylRS* variants through ribosomal incorporation of Bta. *MmPylRS-SMG* showed higher fluorescence intensity than other synthetase variants. Control setup is without induction and ncAA supplementation; no ncAA: control with IPTG induction but without Trp or Bta supplementation, respectively. Trp supplementation did not lead to pronounced signal changes (cf. no ncAA samples). Data are means  $\pm$  SD ( $n = 3$ ).






### Supplementary Figure S4

Comparison Bta incorporation efficiency between codon-optimized *MmPylRS*-coSMG (coSMG) and unoptimized *MmPylRS*-SMG (SMG). Intact cell fluorescence was generated through suppression of the amber stop codon in the sfGFP-R2TAG reporter gene. Different *MmPylRS* setups were tested for Trp and Bta incorporation. Control setup is without induction and ncAA supplementation; no ncAAs: control with IPTG induction but without Trp or Bta supplementation, respectively. Data are means  $\pm$  SD (n = 3).




## Supplementary Figure S5

Comparison of Bta incorporation efficiency by *MmPylRS*-SMG variants with mutagenesis of additional aaRS positions (T13, V31, I36, T56, R61, H62, H63, A100, and S193). Intact cell fluorescence was generated through suppression of the amber stop codon in the sfGFP-R2TAG reporter gene. Different *MmPylRS* setups were tested for Trp or Bta incorporation. Control setup is without induction and ncAA supplementation; no ncAAs: control with IPTG induction but without Trp or Bta supplementation, respectively. Data are means  $\pm$  SD (n = 3).




## Supplementary Figure S6

Comparison of Bta incorporation efficiency by *MmPylRS*-SMG co-expression upon full mutagenesis of aaRS position S193. Intact cell fluorescence was generated through suppression of the amber stop codon in the sfGFP-R2TAG reporter gene. Different *MmPylRS* variants were tested for Trp or Bta incorporation. Control setup is without induction and ncAA supplementation; no ncAAs: control with IPTG induction but without amino acids supplementation. Data are means  $\pm$  SD (n = 3).




### Supplementary Figure S7

Comparison of Bta incorporation efficiency by *Mm*PyIRS-SMG variants with mutagenesis of additional aaRS positions (T13, V31, I36, T56, R61, H62, H63, and A100) combined with S193R replacement. Intact cell fluorescence was generated through suppression of the amber stop codon in the sfGFP-R2TAG reporter gene. Different *Mm*PyIRS variants were tested for Trp or Bta incorporation. Control setup is without induction and ncAA supplementation; no ncAAs: control with IPTG induction but without Trp or Bta supplementation, respectively. Data are means  $\pm$  SD (n = 3).



### Supplementary Figure S8


SDS-PAGE of SUMO-sfGFP (R2TAG) expression in presence of 1 mM Bta with co-expression of *MmPyIRS-SMG*, *MmPyIRS-coSMG* (codon-optimized gene variant), *MmPyIRS-KYR\_SMG*, or *MmPyIRS-13IPYER\_SMG*, respectively. (M: protein ladder; 1: whole cell extract non-induced; 2: whole cell extract with 1 mM IPTG induction and 1 mM Bta; 3: cell lysate; 4: affinity column flow-through; 5: wash fraction with 20 mM imidazole in PBS buffer; 6: elution fraction with 300 mM imidazole in PBS buffer). (FL = full-length, TR= truncated product).



## Supplementary Figure S9


Deconvoluted ESI-MS spectra of purified sfGFP modified by site-specific incorporation of ncAAs. Observed and calculated intact protein masses are as follows: sfGFP-R2 3-MeY calculated is 27774.3 Da, observed is 27774 Da; sfGFP-R2 1-MeW calculated is 27797.3 Da, observed are 27726 Da (background signal) and 27796 Da; sfGFP-R2 AzAla calculated is 27794.3 Da, observed are 27725 Da (background signal) and 27794 Da; sfGFP-R2 2-NaA calculated is 27794.3 Da, observed is 27794 Da; sfGFP-R2 Bpa calculated is 27848.3 Da, observed is 27848 Da. Background signal: The theoretical mass of sfGFP with glutamine (Gln) incorporation is 27725 Da.)

Commonly referred to as near-cognate suppression, Gln incorporation is known to occur naturally in *E. coli* at amber stop codon sites, with the endogenous  $\text{tRNA}_{\text{CUG}}^{\text{Gln}}$  recognizing the UAG codon [1–4]).




## Supplementary Figure S10

Comparison between the expression of wild-type (amber codon free) sfGFP and the suppression of the amber stop codon at sfGFP position 2 (sfGFP-R2TAG) by screened *MmPyIRS* variants. Fluorescence was generated by reporter gene (wt-sfGFP) expression as well as by suppression of the amber stop codon located in the reporter gene (sfGFP-R2TAG) mediated by different *MmPyIRS* variants through ribosomal incorporation of Bta. Control setup is without induction, AAs and ncAAs supplementation; no ncAAs: control with IPTG induction but without Trp or Bta supplementation, respectively. Data are means  $\pm$  SD (n = 3).



## Supplementary Figure S11

Comparing the expression of wt-sfGFP and the suppression of the amber stop codon in sfGFP (sfGFP-R2TAG) by Bta incorporation via screened *MmPylRS* variants in different growth media. The setup of the sfGFP-R2TAG controls lacks the o-pair plasmid. Data are means  $\pm$  SD (n = 3).




\* Auto-induction medium: 0.5% glycerol, 0.075% glucose, 0.05%  $\alpha$ -Lactose monohydrate, 2 mM MgSO<sub>4</sub>, 0.45% Monosodium succinate (pH 6.8), 25 mM Na<sub>2</sub>HPO<sub>4</sub>, 25 mM KH<sub>2</sub>PO<sub>4</sub>, 50 mM NH<sub>4</sub>Cl, 5 mM Na<sub>2</sub>SO<sub>4</sub>, trace metals (10  $\mu$ M FeCl<sub>3</sub>, 4  $\mu$ M CaCl<sub>2</sub>, 2  $\mu$ M MnCl<sub>2</sub>, 2  $\mu$ M ZnSO<sub>4</sub>, 0.4  $\mu$ M CoCl<sub>2</sub>, 0.4  $\mu$ M CuCl<sub>2</sub>, 0.4  $\mu$ M NiCl<sub>2</sub>, 0.4  $\mu$ M Na<sub>2</sub>MoO<sub>4</sub>, 0.4  $\mu$ M Na<sub>2</sub>SeO<sub>3</sub>, 0.4  $\mu$ M H<sub>3</sub>BO<sub>3</sub>), 0.2 mg/mL amino acids (each) [5].

\* LB medium: 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl.




## Supplementary Figure S12

Deconvoluted ESI-MS spectra of purified sfGFP modified by site-specific incorporation of Bta.



A. Deconvoluted ESI-MS spectra of purified sfGFP-R2\_Bta produced by *MmPylRS-KYR\_SMG* variant co-expression in rich media. The calculated molecular mass is 27800 Da whereas the observed mass is 27800 Da.



B. Deconvoluted ESI-MS spectra of purified sfGFP-R2\_Bta produced by *MmPylRS-13IPYER\_SMG* variant co-expression in rich media. The calculated molecular mass is 27800 Da whereas the observed mass is 27800 Da.

## Supplementary Table 1

Information on *MmPylRS* variants used in this study. The usage of codon-optimized genes for aaRS co-expression is indicated by “co”. Please note the scheme used to discriminate between the two Ile mutations at aaRS position 13 and 36, respectively.

Name	Mutations
<i>MmPylRS</i> -SM	N346S/C348M
<i>MmPylRS</i> -GQ	N346G/C348Q
<i>MmPylRS</i> -GM	N346G/C348M
<i>MmPylRS</i> -SMG	N346S/C348M/V401G
<i>MmPylRS</i> -GQG	N346G/C348Q/V401G
<i>MmPylRS</i> -GML	N346G/C348M/W417L
<i>MmPylRS</i> -MLA_GQ	L305M/Y306L/L309A/N346G/C348Q
<i>MmPylRS</i> -MLS_SM	L305M/Y306L/L309S/N346S/C348M
<i>MmPylRS</i> -IV_SMG	T13I/I36V/N346S/C348M/V401G
<i>MmPylRS</i> -IPYE_SMG	V31I/T56P/H62Y/A100E/N346S/C348M/V401G
<i>MmPylRS</i> -KYR_SMG	R61K/H63Y/S193R/N346S/C348M/V401G
<i>MmPylRS</i> -IVR_SMG	T13I/I36V/S193R/N346S/C348M/V401G
<i>MmPylRS</i> -IPYER_SMG	V31I/T56P/H62Y/A100E/S193R/N346S/C348M/V401G
<i>MmPylRS</i> -13IPYE_SMG	T13I/T56P/H62Y/A100E/N346S/C348M/V401G
<i>MmPylRS</i> -13IPYER_SMG	T13I/T56P/H62Y/A100E/S193R/N346S/C348M/V401G
<i>MmPylRS</i> -IIPYE_SMG	T13I/V31I/T56P/H62Y/A100E/N346S/C348M/ V401G
<i>MmPylRS</i> -IIPYER_SMG	T13I/V31I/T56P/H62Y/A100E/S193R/N346S/ C348M/V401G
<i>MmPylRS</i> -SMGL	N346S/C348M/V401G/W417L
<i>MmPylRS</i> -SMGK	N346S/C348M/V401G/W417K
<i>MmPylRS</i> -SMGI	N346S/C348M/V401G/W417I
<i>MmPylRS</i> -KYR_SMGL	R61K/H63Y/S193R/N346S/C348M/V401G/ W417L
<i>MmPylRS</i> -KYR_SMGK	R61K/H63Y/S193R/N346S/C348M/V401G/ W417K
<i>MmPylRS</i> -KYR_SMGI	R61K/H63Y/S193R/N346S/C348M/V401G/ W417I
<i>MmPylRS</i> -SML	N346S/C348M/W417L
<i>MmPylRS</i> -SMV	N346S/C348M/W417V
<i>MmPylRS</i> -KYR_SML	R61K/H63Y/S193R/N346S/C348M/W417L
<i>MmPylRS</i> -KYR_SMI	R61K/H63Y/S193R/N346S/C348M/W417I
<i>MmPylRS</i> -coSMG	N346S/C348M/V401G (codon-optimized)
<i>MmPylRS</i> -coS193R_SMG	S193R/N346S/C348M/V401G (codon-optimized)
<i>MmPylRS</i> -coKYR_SMG	R61K/H63Y/S193R/N346S/C348M/V401G (codon-optimized)

## Supplementary Table 2






Layout of the amino acids screening system used for *MmPylRS* variants in 96-well plate format.

	1	2	3	4	5	6	7	8	9	10	11	12
A	W/O	W/O	Met	Ala	Gly	Phe	Trp	Tyr	Val	Cys	His	Pro
B	No AAs	No AAs	Leu	Ile	Lys	Arg	Ser	Thr	Asn	Gln	Glu	Asp
C	1	2	3	4	5	6	7	8	9	10	11	12
D	13	14	15	16	17	18	19	20	21	22	23	24
E	25	26	27	28	29	30	31	32	33	34	35	36
F	37	38	39	40	41	42	43	44	45	46	47	48
G	49	50										
H												



➤ W/O: control without AAs, ncAAs, and IPTG induction; No AAs: control with IPTG induction but without amino acids supplementation.







### Supplementary Table 3

Non-canonical amino acids (ncAAs) used in this study.

No.	Name	CAS No.	Company	Structure
1	5-Cyano- <i>DL</i> -Tryptophan (5-CNW)	2089602-82-2	Biosynth	
2	5-Hydroxy- <i>L</i> -Tryptophan (5-OHW)	145224-90-4	Biosynth	
3	5-Bromo- <i>DL</i> -Tryptophan (5-BrW)	6548-09-0	Biosynth	
4	6-Bromo- <i>DL</i> -Tryptophan (6-BrW)	33599-61-0	Biosynth	
5	7-Bromo- <i>DL</i> -Tryptophan (7-BrW)	852391-45-8	Biosynth	

6	4-Chloro- <i>L</i> -Tryptophan (4-CIW)	52448-14-3	Biosynth	
7	5-Chloro- <i>DL</i> -Tryptophan (5-CIW)	154-07-4	Biosynth	
8	6-Chloro- <i>DL</i> -Tryptophan (6-CIW)	17808-21-8	abcr GmbH	
9	5-Amino- <i>DL</i> -Tryptophan (5-NH <sub>2</sub> W)	6383-69-3	Biosynth	
10	3-(2-Naphthyl)- <i>L</i> -Alanine (2-NaA)	14108-60-2	abcr GmbH	
11	5-Methoxy- <i>DL</i> -Tryptophan (5-MeOW)	28052-84-8	Biosynth	


12	5-Methoxy- <i>L</i> -Tryptophan (5-MeOW)	25197-96-0	Biosynth	
13	4-Benzoyl- <i>L</i> -Phenylalanine (Bpa)	104504-45-2	BACHEM	
14	4-Methyl- <i>DL</i> -Tryptophan (4-MeW)	1954-45-6	Biosynth	
15	5-Methyl- <i>DL</i> -Tryptophan (5-MeW)	951-55-3	Merck & Sigma	
16	6-Methyl- <i>DL</i> -Tryptophan (6-MeW)	2280-85-5	Biosynth	

17	7-Methyl- <i>DL</i> -Tryptophan (7-MeW)	17332-70-6	Biosynth	
18	7-Chloro- <i>L</i> -Tryptophan (7-ClW)	153-97-9	Biosynth	
19	1-Methyl- <i>DL</i> -Tryptophan (1-MeW)	21339-55-9	Merck & Sigma	
20	2,5-Difluoro- <i>DL</i> -Phenylalanine	32133-38-3	Biosynth	
21	2,6-Difluoro- <i>DL</i> -Phenylalanine	32133-39-4	Biosynth	
22	3,5-Difluoro- <i>DL</i> -Phenylalanine	32133-37-2	Biosynth	

23 3,4-Difluoro-*DL*-Phenylalanine

32133-36-1


Alfa Aesar



24 2,3-Difluoro-*DL*-Phenylalanine

236754-62-4


abcr GmbH



25 3-(2-Naphthyl)-*L*-Alanine  
(1-NaA)

55516-54-6


BACHEM



26 3,4-Difluoro-*DL*-Phenylglycine

225641-94-1


abcr GmbH



27 4-Trifluoromethyl-*L*-Phenylalanine  
(4-CF<sub>3</sub>W)

114926-38-4

Alfa Aesar






28

3-Fluoro-*DL*-Tyrosine  
(3-FluY)

403-90-7

Alfa Aesar




29

2,3,5,6-Tetrafluorotyrosine

157807-84-6

Merck &amp; Sigma




30

H-4-(7-Hydroxycoumarin-4-yl)-Abu-OH  
(Coumarin)

905442-42-4

BACHEM




31

3-Benzothieryl-*L*-Alanine  
(Bta)

72120-71-9

BACHEM




32

3-Chloro-L-Tyrosine  
(3-ClY)

7423-93-0

Alfa Aesar




33

3-Bromo-L-Tyrosine  
(3-BrY)

38739-13-8

abcr GmbH




34

3,5-Dichloro-L-Tyrosine  
(3,5-diClY)

15106-62-4

abcr GmbH




35

3,5-Dibromo-L-Tyrosine  
(3,5-diBrY)

300-38-9

BACHEM




36

$\beta$ -(1-Azulenyl)-L-Alanine  
(AzAla)

273408-71-2

It was synthesized by our  
lab as reported previously  
[6,7]




37

2-Amino-4-(Methylsulfinyl)Butanoic acid  
(Methionine sulfoxide)

62697-73-8

Alfa Aesar




38

4-Fluoro-DL-Tryptophan  
(4-FluW)

25631-05-4

Biosynth




39

5-Fluoro-DL-Tryptophan  
(5-FluW)

154-08-5

abcr GmbH




40

5-Nitro-DL-Tryptophan  
(5-NO<sub>2</sub>W)

6525-46-8

Biosynth




41

4-Nitro-DL-Phenylalanine  
(4-NO<sub>2</sub>F)

2922-40-9

BACHEM




42

DL-7-Azatryptophan  
(7-AzaW)

7303-50-6

abcam








43

3,4-Dihydroxy-L-Phenylalanine  
(L-Dopa)

59-92-7

Merck & Sigma



44	4-Cyano-L-Phenylalanine (4-CNF)	167479-78-9	Alfa Aesar	
45	4-Azido-DL-Phenylalanine (4-N <sub>3</sub> F)	33173-35-4	BACHEM	
46	4-Amino-L-Phenylalanine (4-NH <sub>2</sub> F)	943-80-6	Alfa Aesar	
47	3-Amino-DL-Tyrosine (3-NH <sub>2</sub> Y)	23279-22-3	BACHEM	

48	3-Nitro-DL-Tyrosine (3-NO <sub>2</sub> Y)	621-44-3	Alfa Aesar	
49	3-Methyl-L-Tyrosine (3-MeY)	6230-11-1	Alfa Aesar	
50	3-Iodo-L-Tyrosine (3-IodY)	70-78-0	TCI	

---

## Reference

42. Muzika, M.; Muskat, N.H.; Sarid, S.; Ben-David, O.; Mehl, R.A.; Arbely, E. Chemically-defined lactose-based autoinduction medium for site-specific incorporation of non-canonical amino acids into proteins. *RSC Adv.* **2018**, *8*, 25558–25567, doi:10.1039/c8ra04359k.
63. Beyer, J.N.; Hosseinzadeh, P.; Gottfried-Lee, I.; van Fossen, E.M.; Zhu, P.; Bednar, R.M.; Karplus, P.A.; Mehl, R.A.; Cooley, R.B. Overcoming Near-Cognate Suppression in a Release Factor 1-Deficient Host with an Improved Nitro-Tyrosine tRNA Synthetase. *J. Mol. Biol.* **2020**, *432*, 4690–4704, doi:10.1016/j.jmb.2020.06.014.
65. Schumacher, D.; Lemke, O.; Helma, J.; Gerszonowicz, L.; Waller, V.; Stoschek, T.; Durkin, P.M.; Budisa, N.; Leonhardt, H.; Keller, B.G.; Hackenberger, C. P. R. Broad substrate tolerance of tubulin tyrosine ligase enables one-step site-specific enzymatic protein labeling. *Chem. Sci.* **2017**, *8*, 3471–3478, doi:10.1039/C7SC00574A.
66. Loidl, G.; Musiol, H.J.; Budisa, N.; Huber, R.; Poirot, S.; Fourmy, D.; Moroder, L. Synthesis of [beta]-(1-azulenyl)-L-alanine as a potential blue-colored fluorescent tryptophan analog and its use in peptide synthesis. *J. Pept. Sci.* **2000**, *6*, 139–144.
67. Aerni, H.R.; Shifman, M.A.; Rogulina, S.; O'Donoghue, P.; Rinehart, J. Revealing the amino acid composition of proteins within an expanded genetic code. *Nucleic Acids Res.* **2015**, *43*, 8, doi:10.1093/nar/gku1087.
68. Inokijchi, H.; Kodaira, M.; Yamao, F.; Ozeki, H. Identification of transfer RNA suppressors in *Escherichia coli*: II. Duplicate genes for tRNA<sup>2Gln</sup>. *J. Mol. Biol.* **1979**, *132*, 663–677, doi:10.1016/0022-2836(79)90381-4.
69. Ogawa, A.; Hayami, M.; Sando, S.; Aoyama, Y. A Concept for Selection of Codon-Suppressor tRNAs Based on Read-Through Ribosome Display in an In Vitro Compartmentalized Cell-Free Translation System. *J. Nucleic Acids* **2012**, *2012*, 7, doi:10.1155/2012/538129.